Introduction
• Non-communicable diseases (NCDs) account for the majority of adult deaths worldwide, and 80% of these deaths occur in low and middle-income countries (LMICs). 1 • The burden of NCDs in LMICs is predicted to grow with improvements in sanitation and infectious disease control, and will be altered by local diet, smoking rates, and HIV co-infection. 2 • There is a critical need to identify and implement low-cost, wellvalidated diagnostic tests to elucidate the epidemiology of NCDs, and enable diagnostic monitoring and therapeutic interventions. 3 • Tests that enable non-healthcare professionals to lead care provision will augment the scalability of this strategy.
• In 2010, the WHO recommended a package of essential noncommunicable disease technologies for use in low-resource settings including a digital blood pressure measurement device, electrocardiograph, and glucometer. 4 • Validation of such tools in appropriate settings will be crucial to developing a strategy for strengthening health systems to address the growing burden of NCDs.
We recently completed implementation and evaluation of a bundle of point-of-care, low-cost diagnostics for NCD measurement in rural Uganda. The objective was to assess the feasibility, reproducibility, and cost of testing in a resource-poor setting for a variety of cardiovascular conditions including hypertension, diabetes, and subclinical atherosclerosis. 
Design

Statistical Analysis
We assessed the quality and feasibility of each measurement by: 
Methods
Results Discussion
105 HIV-infected and 100 HIV-uninfected individuals were enrolled in the study. In total, there were 101 males (49.3%) and 104 females (50.7%) with a median age of 49 years.
Diabetes screening
None of the 205 total HbA1c tests were invalid. The coefficient of determination between the Hb1c and fasting plasma glucose levels was 0.65.
Conclusion
Following a modified WHO framework (Box 1), we are able to outline the appropriateness of our diagnostics:
Affordability
• In Uganda, estimated annual per-patient lab costs for HIV care is 111,000 Ugandan shillings, or about $45 USD. 7 • Over three years the perpatient costs of our bundle of tests would be $28 USD, which is within range of the Ugandan HIV lab costs or similar NCD diagnostics done in the US.
Validity
• All HbA1c tests were valid and results correlated with fasting plasma glucose levels.
• Low-cost, portable, and well-validated point-of-care tests for NCDs can be implemented by non-medical professionals in LMICs.
• Implementation evaluations should be pursued to assess the largescale feasibility, scalability, and impact of this strategy. 
Carotid intima-media thickness quality assessment
Of the 1213 CIMT images reviewed, 1024 (84.4%) were found to be of adequate quality for interpretation (average score: 1.4 ± 0.7). 98% of participants had at least 4 valid images necessary to calculate a mean CIMT.
Blood pressure screening
The right and left brachial blood pressure measurements had coefficients of determination of 0.78 and 0.71, respectively, with the automated systolic blood pressure measurements.
Cost estimates
Based on an estimate patient volume of 1,000 patients per year and measurement for 3 years, the cost for this array of tests, including capital equipment, would be approximately $28 per patient. • Rapid treatment at the first visit and robust use without the need for special storage
• Equipment-free (note: portable handheld battery-operated devices are acceptable)
• Delivered to those who need it
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